To Report an Adverse Event, Medical Device Report, Other Safety Finding or Product Complaint:

Call: 1-800-453-6948
Email: [email protected]

Vericel is committed to patient safety. Part of our mission to serve patients includes collecting, reviewing and reporting all adverse events, other safety findings, medical device reports and product complaint information associated with the use of Vericel's investigational and marketed products.

It is Vericel's policy to comply with all regulations and laws relating to reporting adverse events, other safety findings, medical device reports and product complaints.

Adverse Event (AE)

An AE is any untoward medical occurrence in a patient administered a Vericel product and which is not necessarily caused by the Vericel product. An AE can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, combination product, or medical device, whether or not considered related to the product. This includes:

  • Any clinically significant worsening of a pre-existing condition;
  • An AE that has been associated with the discontinuation of the use of a product; and
  • Any lack or loss of intended effect.

Other Safety Findings

The following are considered Other Safety Findings regardless of whether they are associated with an AE and they must be reported to Vericel:

  • Use of a Vericel product while pregnant and/or breast feeding
  • Accidental or intentional medication errors or overdose of a Vericel product
  • Misuse, where the Vericel product is intentionally and inappropriately used including misuse for illegal purposes
  • Abuse, which is, intentional excessive use of a Vericel product
  • Transmission of an infectious agent through a contaminated Vericel product
  • Occupational exposure to a Vericel product (e.g., a Healthcare Provider is splashed with medicinal product while preparing an injection)
  • Reports of patient "death" after exposure to a Vericel product where no other details are provided (e.g. fatal outcomes)
  • Off-label use of a Vericel product (e.g. a product is intentionally used to treat a condition for which the product is not indicated).

Medical Device Report (MDR)

The following are considered MDRs

  • An event that reasonably suggests that the Vericel device:
    • May have caused or contributed to a death or serious injury including events occurring as a result of:
      • Failure
      • Malfunction
      • Improper or inadequate design
      • Manufacture
      • Labeling
      • User error
    • Has malfunctioned and that the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur

Product Complaints (PC)

A PC includes any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a drug, combination product, or device after it is released for distribution to market or clinic by either Vericel or by distributors and partners for whom Vericel manufactures the material. This includes all components distributed with the drug such as packaging, drug containers, delivery system, labelling, inserts, etc. Examples include:

  • Device that is damaged or broken
  • Bent or dull needles
  • Missing or illegible labeling
  • Inability of customer to administer the product
  • Product with an unexpected color, appearance, or particles

To Report an Adverse Event, Medical Device Report, Other Safety Finding or Product Complaint:

Call: 1-800-453-6948
Email: [email protected]

Important Safety Information

Indication

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

  • Chemical or electrical burns
  • Burns on the face, perineum, or genitalia
  • Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
  • Circumferential burns
  • Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.

Important Safety Information

Contraindications

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

Important Safety Information

Indication

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

  • Chemical or electrical burns
  • Burns on the face, perineum, or genitalia
  • Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
  • Circumferential burns
  • Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.

Important Safety Information

Contraindications

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb.

Pain Management

Manage pain as appropriate for an extensive dressing change of burn wounds. At least 15 minutes prior to NEXOBRID-related procedures ensure adequate pain control measures are in place.

Proteolytic Injury to Non-Target Tissues

NEXOBRID is not recommended for treatment of burn wounds where medical devices or vital structures could become exposed during eschar removal.

Coagulopathy

Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.

Adverse Reactions

The most common adverse reactions (>10%) were pruritus and pyrexia.

Use in Special Populations
Geriatric Use

Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.